X

Trial Profile

An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exenatide (Primary)
Indications Type 2 diabetes mellitus
Focus Adverse reactions; Pharmacodynamics; Registrational
Sponsors Amylin Pharmaceuticals; Bristol-Myers Squibb

Most Recent Events

19 Jun 2009 Planned number of patients changed from 50 to 58 as reported by ClinicalTrials.gov.
19 Jun 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
02 Jun 2008 The expected completion date for this trial has been extended from May 2008 to Jun 2008 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com